JAMA Oncology
@jamaonc
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
ID: 2811548749
http://ja.ma/tjamaoncology 15-09-2014 15:33:04
17,17K Tweet
47,47K Followers
542 Following
Most viewed in the last 7 days from JAMA Otolaryngology – Head & Neck Surgery: Are CD44 and total protein useful for monitoring head and neck cancer recurrence, either used in a point-of-care test or as individual laboratory-based biomarkers? ja.ma/470GY3D
Listen to an interview with Michelle Rengarajan, author of "Identification of Immune Checkpoint Inhibitor–Induced Diabetes," and Vivek Subbiah, MD. Hosted on AMA Ed Hub™. ja.ma/3WZvYPs
Most viewed in the last 7 days from JAMA Oncology: How frequently do cardiovascular adverse events occur in patients treated with immune checkpoint inhibitors and how should clinicians manage myocarditis in particular? ja.ma/3X3Pvy9
From JAMA Surgery: Unlocking insights in liver cancer treatment: study compares LR, PRFA, and TACE in patients with multinodular BCLC-A, revealing superior survival with LR. Therapeutic hierarchy holds in these cases. ja.ma/3Me4sIR #LiverCancer #SuperiorSurvival
From JAMA Network Open: Study finds racial disparities in adolescent & young adult (AYA) cancer outcomes. Indigenous population have lower cancer survival rates for cancers w/ widest survival gaps. Indigenous inclusion is necessary in AYA cancer research. ja.ma/3XldhqN
⭐️Identification of Immune Checkpoint Inhibitor–Induced Diabetes - was just published JAMA Oncology JAMA 👉🏼 Delighted to host a podcast with the lead author Dr. Michelle Rengarajan, Physician-scientist Harvard Medical School MassGeneral News Hosted on AMA Ed Hub™
Authors Heather McGee, MD PhD Terry Williams and Percy Lee MD explain differences between recent studies using radiotherapy with immunotherapy and possible reasons for their different outcomes. ja.ma/3Xa4S8y City of Hope - Department of Radiation Oncology
⭐️Nice editorial on “Neoadjuvant Immunotherapy in Breast Cancer - from #ClinicalTrials to #Practice” Dr. E Mittendorf Sara Tolaney JAMA Oncology JAMA jamanetwork.com/journals/jamao…
From JAMA Network Open: People w/ or without blood cancers had similar rates of cognitive decline before, around the time & after diagnosis, suggesting the cognitive trajectory of older adults with blood cancer parallels the trajectory seen in normal aging. ja.ma/4dIC1iA
Most viewed in the last 7 days from JAMA Oncology: How frequently do cardiovascular adverse events occur in patients treated with immune checkpoint inhibitors and how should clinicians manage myocarditis in particular? ja.ma/3Mq1rFD